Corventum Receives FDA IND Clearance for CVT-130, First-in-Class Cardioprotective Agent for Anthracycline Chemotherapy
核心洞察
The FDA has cleared Corventum (搜索)'s IND application for CVT-130 (搜索), a first-in-class metabolic modulator designed to prevent anthracycline (搜索)-related cardiotoxicity (搜索) while preserving anti-tumor efficacy.
CVT-130 (搜索) addresses a critical limitation in cancer (搜索) treatment, as anthracyclines are used in over two million patients annually but cause cumulative cardiac damage that prevents retreatment.
The company plans to initiate a randomized, placebo-controlled Phase 1 trial in healthy volunteers during the second quarter of 2026 to evaluate safety and optimal dosing.
Corventum (搜索), Inc. announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application for CVT-130 (搜索), a first-in-class metabolic modulator designed to prevent anthracycline (搜索)-related cardiotoxicity (搜索). The Boston and Salt Lake City-based company plans to initiate a first-in-human Phase 1 clinical trial in the second quarter of 2026.
CVT-130 (搜索) represents a potential breakthrough in addressing one of oncology's most persistent challenges. Anthracyclines, including doxorubicin, epirubicin, and daunorubicin, are among the most effective cancer (搜索) drugs developed and are used in more than two million patients each year. However, their clinical utility is severely limited by cumulative, dose-dependent cardiac damage that can lead to heart failure (搜索) and reduced long-term survival.
Addressing Critical Treatment Limitations
"Anthracyclines have saved countless lives, yet the use of these highly effective chemotherapies is limited by cumulative heart damage that can appear months or years after treatment," said Randall Peterson, Ph.D., Corventum (搜索) co-founder, CVT-130 (搜索) co-inventor, and Dean of the University of Utah College of Pharmacy (搜索). "CVT-130 was designed to protect cardiac cells from damage caused by anthracyclines, potentially allowing more patients to benefit from these widely used cancer (搜索) treatments and enabling retreatment in recurrent disease."
The current treatment paradigm forces oncologists to balance cancer (搜索) efficacy against cardiac safety. Once patients reach their lifetime anthracycline (搜索) dose limit, retreatment becomes impossible even if their cancer recurs, forcing reliance on less effective alternatives. This limitation affects treatment outcomes for patients with recurrent cancers who could benefit from additional anthracycline therapy.
Preclinical Evidence and Mechanism
CVT-130 (搜索) is designed to modulate mitochondrial and metabolic pathways (搜索) to prevent anthracycline (搜索)-induced cardiac injury while preserving mitochondrial function. The drug's room-temperature stable formulation allows rapid injection prior to anthracycline chemotherapy administration.
"Our preclinical data show that CVT-130 (搜索) prevents cardiac injury while maintaining full anti-tumor potency, a balance that no therapy has achieved to date," said Aarti Asnani, M.D., Corventum (搜索) co-founder, CVT-130 co-inventor, and Chair of the Cardio-Oncology Committee of the American Heart Association. "With FDA clearance of the IND, we can now advance CVT-130 to the clinic and take the next step toward delivering a therapy that could benefit millions of patients worldwide who depend on anthracyclines for cancer (搜索) treatment."
Phase 1 Trial Design
The planned randomized, placebo-controlled Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CVT-130 (搜索) in healthy volunteers. The study will also assess cardiac and mitochondrial biomarkers to better understand the drug's mechanism of action and optimal dosing parameters.
The trial is designed to identify an optimal dose for a subsequent Phase 2 trial in cancer (搜索) patients. Corventum (搜索) worked closely with the FDA to align on the Phase 1 study design, which reflects the intended dosing strategy for the Phase 2 clinical trial.
Broader Therapeutic Potential
Beyond its primary indication for anthracycline (搜索) cardioprotection, CVT-130 (搜索) is being developed to address additional diseases involving mitochondrial dysfunction (搜索). This broader therapeutic potential could expand the drug's clinical utility beyond oncology applications.
The FDA clearance represents a significant milestone for Corventum (搜索), a company focused on developing novel therapies that make existing cancer (搜索) treatments safer and more effective. The advancement of CVT-130 (搜索) to clinical trials could potentially transform how oncologists approach anthracycline (搜索)-based chemotherapy regimens, offering hope for improved outcomes in cancer patients who require these highly effective but cardiotoxic treatments.